NASHVILLE, Tenn. / Sep 28, 2023 / Business Wire / HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that 32 of its hospitals have been recognized on the 2023 Fortune/PINC AI 100 Top Hospitals list for excellence in patient outcomes and experience, operational efficiency, financial health and community impact. The esteemed list aims to inspire hospital and health system leaders to strive for higher performance and provide added value to the patients and communities they serve.
“We are incredibly proud of our colleagues and caregivers for their dedication to excellence, which has earned more than 30 of our hospitals a spot on the 100 Top Hospitals list,” said Dr. Michael Cuffe, executive vice president and chief clinical officer of HCA Healthcare. “This honor recognizes HCA Healthcare’s steadfast commitment to providing our patients with high-quality care.”
According to Fortune/PINC AI, this year’s 100 Top Hospitals study used a balanced scorecard approach focused on clinical, operational, financial, and patient perception to evaluate 2,644 short-term, acute care, non-federal U.S. hospitals. Unlike ranking programs that require hospitals to apply for evaluation, the program is strictly based on performance and publicly available data, including Medicare reports and patient satisfaction data.
In comparison to other hospitals, the study found the top 100 hospitals had better outcomes, including lower mortality rates, fewer complications, lower healthcare associated infection rates and shorter lengths of stay.
In addition to scoring among the top 100, 18 HCA Healthcare hospitals received the Everest Award for setting national benchmarks for the fastest, most consistent improvement rates and highest current year performance. This additional distinction recognizes the dedication of the boards, executives and medical staff leaders who developed and executed the strategies that helped drive the highest rates of performance improvement over the five-year period measured in the study.
HCA Healthcare’s recognized teaching facilities and large, medium and small community hospitals throughout our organization, include:
HCA Healthcare Top Major Teaching Hospitals
HCA Healthcare Top Teaching Hospitals
HCA Healthcare Large Community Hospitals
HCA Healthcare Medium Community Hospitals
HCA Healthcare Small Community Hospitals
About HCA Healthcare
Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 182 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. With its founding in 1968, HCA Healthcare created a new model for hospital care in the United States, using combined resources to strengthen hospitals, deliver patient-focused care and improve the practice of medicine. HCA Healthcare has conducted a number of clinical studies, including one that demonstrated that full-term delivery is healthier than early elective delivery of babies and another that identified a clinical protocol that can reduce bloodstream infections in ICU patients by 44%. HCA Healthcare is a learning health system that uses its more than 37 million annual patient encounters to advance science, improve patient care and save lives.
All references to “Company,” “HCA” and “HCA Healthcare” as used throughout this document refer to HCA Healthcare, Inc. and its affiliates.
Last Trade: | US$297.75 |
Daily Change: | -2.40 -0.80 |
Daily Volume: | 936,024 |
Market Cap: | US$75.420B |
October 25, 2024 October 17, 2024 July 23, 2024 April 26, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB